Renal Disease
Hepatitis C treatment receives new indication in Europe
Published in Hepatitis Weekly, December 6th, 2004
The company said that this extension of the current label is based on the results of a study that showed combination therapy with Pegasys eradicated the virus (sustained virological response) in more than half of this patient group. Under current treatment guidelines, hepatitis C patients with normal liver enzymes would not normally be eligible for treatment.
According to the announcement, the EMEA has recognized that patients who have normal alanine...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2004-12-06)
More Articles from Hepatitis Weekly
- Cancer Risk Factor
Hepatitis C infection encourages liver cancer recurrence after resection - Immunization
Accelerated hepatitis B vaccine schedules protect prisoners better - Immunosuppressive Therapy
Drug selection has little impact on hepatitis C severity after liver grafts - Mutagenesis
A new transfection protocol improves the study of hepatitis B virus mutants - Transplant Medicine
Biopsies done a year after liver transplantation predict fibrosis progression - Adverse Side Effects
Rare cutaneous reactions arise following hepatitis B vaccine immunization - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
